Sorin Group Receives Regulatory Approval for New Generation MRI Compatible...
TOKYO Sorin Group, (Reuters Code: SORN.MI), a global medical device company and a leader in the treatment of cardiovascular diseases, announced today that it has received approval from Japan’s...
View ArticleテラヴェクティスがBpifranceより190万ユーロの資金を調達
パリ (ビジネスワイヤ) — 世界の主要な感染性疾患とがんに対する新世代の治療用ワクチンと免疫療法の開発を専門とするフランスのバイオテクノロジー企業テラヴェクティスは、Bpifranceより、イノベーション発展支援プログラム(ADI)の一環として、返済可能な前払い金の形で、190万ユーロの助成金を交付されたと発表しました。...
View ArticleTakeda Announces That the First Interim Analysis of the Phase 3 Study of Oral...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) today announced that the randomized, double-blind, placebo-controlled TOURMALINE-MM1 pivotal Phase 3 trial...
View ArticleRosetta Genomics Receives First Patent Allowance in Japan
PRINCETON, N.J. & REHOVOT, Israel Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company received a Notice of...
View ArticleLabcyte Commends Institute for Molecular Medicine Finland – Pfizer Leukemia...
SUNNYVALE, Calif. Labcyte, a company revolutionizing life science research with its patented acoustic liquid handling technology, today praised the results of an international collaboration between...
View ArticleThe Philippines is the 19th Country to Clear CEL-SCI for Patient Enrollment...
VIENNA, Va. CEL-SCI Corporation (NYSE MKT: CVM) today announced that the Philippines Regulatory Agency (PFDA) has cleared the Company to commence patient enrollment of the Phase III head and neck...
View ArticleNeurovive Pharmaceutical: New Subsidiary Secures Funding of Just over USD 3 m...
STOCKHOLM Regulatory News: NeuroVive (STO:NVP) has established a subsidiary in Taiwan, NeuroVive Pharmaceutical Asia, Inc., which has secured initial funding totaling USD 3,255 m. The funding is...
View ArticleNew Promega Reagent and Software Tool Monitors Performance of Mass...
MADISON, Wis. Promega Corporation announces the release of the 6 × 5 LC-MS/MS Peptide Reference Mix, a novel reagent and software combination. The reagent monitors LC and MS parameters, while the...
View ArticleVital Connect Receives Medical Device Ninsho Certification to Market...
SAN JOSE, Calif. Vital Connect announced today that it received Medical Device Ninsho certification to market its HealthPatch® MD as a telemetric electrocardiography transmission device and body...
View ArticleWaVe Life Sciencesが立体化学的に純粋な核酸医薬品を前進させるための1800万ドルのシリーズA資金調達を完了
ボストン & 沖縄 (ビジネスワイヤ) – WaVe Life Sciencesは 本日、当初からの出資企業SNBL Ltd.に加え、RA Capital Management, LLCとかごしま新産業創生投資事業有限責任組合が主導した1800万ドルのシリーズA資金調達を完了したと発表しました。調達した資金は、アンチセンス 医薬品およびエキソンスキッピング医薬品など...
View ArticleRainbow Medical Raises $25 Million from Chinese Investors, and Sets Up a...
HERZLIYA, Israel Rainbow Medical, a leading R&D and operational investment company, specializing in seeding and incubating medical device startups and developing breakthrough medical...
View Article细胞再生疗法的先驱CellProthera荣获2014年度UBISTART 奖
法国MULHOUSE (美国商业资讯) — UBIFRANCE和总部在纽约的盖仑基金会将2014年度 UBISTART奖颁发给CellProthera。该奖项旨在表彰法国创新型创业企业在生命科学领域取得的重大进步。...
View ArticlepSivida Announces U.S. Shipments of ILUVIEN® for DME to Start February 23
WATERTOWN, Mass. pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that initial nationwide...
View ArticleEppendorf发布新款CryoCube®超低温冰箱
康涅狄格州恩菲尔德 –(美国商业资讯)–新款CryoCube F570、F570h、FC660和FC660h 超低温冰箱结合了最高的样品安全性和改进的功能性。新改进降低了能耗,使CryoCube 冰箱成为业界能效最高的产品。 CryoCube® F570h, F570, and FC660h Ultra-Low Temperature Freezers from Eppendorf....
View Article細胞再生療法のパイオニア企業セルプロセラが2014年UBISTART賞を受賞
仏ミュルーズ (ビジネスワイヤ) — セルプロセラは、ユビフランス(フランス企業振興機構)とニューヨークを拠点とするガリエン財団が主催する2014年UBISTART賞を受賞しました。このイニシアチブはライフサイエンス分野で大きく前進しているフランスの革新的な新興企業を表彰するものです。...
View Articleエッペンドルフが新しいCryoCube®極低温冷凍庫を発表
米コネティカット州エンフィールド (ビジネスワイヤ) — 新しい極低温冷凍庫のCryoCube F570、F570h、FC660、FC660hは、最高度の試料安全性、そして機能改善を実現しています。新たな技術進歩によって消費電力が減少し、CryoCubeは業界で最もエネルギー効率の高い冷凍庫となっています。 CryoCube® F570h, F570, and FC660h Ultra-Low...
View ArticleCEL-SCI’s Phase III Head and Neck Cancer Trial Cleared to Begin Patient...
VIENNA, Va. CEL-SCI Corporation (NYSE MKT: CVM) today announced the Ministry of Health Malaysia has cleared the Company to commence patient enrollment for its Phase III head and neck cancer trial of...
View ArticleMitobridge Secures Key Intellectual Property from the Salk Institute
CAMBRIDGE, Mass. Mitobridge, Inc., previously known as Mitokyne, Inc., a biopharmaceutical company pioneering the discovery and development of products that improve mitochondrial function, today...
View Article